JP2000500653A - ヒト癌のマウスモデル - Google Patents

ヒト癌のマウスモデル

Info

Publication number
JP2000500653A
JP2000500653A JP9519058A JP51905897A JP2000500653A JP 2000500653 A JP2000500653 A JP 2000500653A JP 9519058 A JP9519058 A JP 9519058A JP 51905897 A JP51905897 A JP 51905897A JP 2000500653 A JP2000500653 A JP 2000500653A
Authority
JP
Japan
Prior art keywords
mouse
cancer
human
immunodeficient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9519058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000500653A5 (2
Inventor
レパスキー サブジェック，エリザベス
バンパース，ハーベイ
セクリスト，ヘザー
Original Assignee
コリクサ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コリクサ コーポレイション filed Critical コリクサ コーポレイション
Publication of JP2000500653A publication Critical patent/JP2000500653A/ja
Publication of JP2000500653A5 publication Critical patent/JP2000500653A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP9519058A 1995-11-13 1996-11-13 ヒト癌のマウスモデル Ceased JP2000500653A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/556,659 US5986170A (en) 1995-11-13 1995-11-13 Murine model for human carcinoma
US08/556,659 1995-11-13
PCT/US1996/018243 WO1997018300A2 (en) 1995-11-13 1996-11-13 Murine model for human carcinoma

Publications (2)

Publication Number Publication Date
JP2000500653A true JP2000500653A (ja) 2000-01-25
JP2000500653A5 JP2000500653A5 (2) 2004-10-21

Family

ID=24222286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9519058A Ceased JP2000500653A (ja) 1995-11-13 1996-11-13 ヒト癌のマウスモデル

Country Status (7)

Country Link
US (2) US5986170A (2)
EP (1) EP0866655B1 (2)
JP (1) JP2000500653A (2)
AT (1) ATE261654T1 (2)
AU (1) AU1158997A (2)
DE (1) DE69631896D1 (2)
WO (1) WO1997018300A2 (2)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098471A1 (ja) * 2009-02-27 2010-09-02 株式会社バイオマトリックス研究所 がん細胞を用いた免疫方法
US8001037B2 (en) 2000-04-13 2011-08-16 Super Derivatives, Inc. Method and system for pricing options
WO2012026615A1 (ja) * 2010-08-25 2012-03-01 株式会社バイオマトリックス研究所 がん細胞を用いた抗体の製造方法
US8423443B2 (en) 2001-10-13 2013-04-16 Super Derivatives, Inc. Method and system for pricing financial derivatives
US8620792B2 (en) 2010-01-04 2013-12-31 Super Derivatives, Inc. Device, method and system of pricing financial instruments

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US6730512B2 (en) * 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
JP2001520011A (ja) * 1997-09-26 2001-10-30 コリクサ コーポレイション ヒトガンについてのマウスモデル
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20050260177A1 (en) * 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US6623923B1 (en) 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6590076B1 (en) * 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) * 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
DK2500360T3 (en) 2005-10-31 2015-10-26 Oncomed Pharm Inc Compositions and methods for the diagnosis and treatment of cancer
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2012145535A2 (en) * 2011-04-19 2012-10-26 H. Lee Moffitt Cancer Center & Research Institute, Inc. Animal model of human cancer and methods of use
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071620T3 (es) * 1987-12-23 1995-07-01 Univ Leland Stanford Junior Mamiferos inmunodeficientes quimericos y su utilizacion.
US5491284A (en) * 1988-10-05 1996-02-13 Anticancer Incorporated Nude mouse model for neoplastic disease
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0481058B1 (en) * 1990-05-03 1996-07-17 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系
AU657838B2 (en) * 1991-08-02 1995-03-23 Systemix, Inc. Primordial implants in immunodeficient hosts
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8001037B2 (en) 2000-04-13 2011-08-16 Super Derivatives, Inc. Method and system for pricing options
US8423443B2 (en) 2001-10-13 2013-04-16 Super Derivatives, Inc. Method and system for pricing financial derivatives
WO2010098471A1 (ja) * 2009-02-27 2010-09-02 株式会社バイオマトリックス研究所 がん細胞を用いた免疫方法
JP5688699B2 (ja) * 2009-02-27 2015-03-25 株式会社オーダーメードメディカルリサーチ がん細胞を用いた免疫方法
US8620792B2 (en) 2010-01-04 2013-12-31 Super Derivatives, Inc. Device, method and system of pricing financial instruments
US8626630B2 (en) 2010-01-04 2014-01-07 Super Derivatives, Inc. Device, method and system of pricing financial instruments
WO2012026615A1 (ja) * 2010-08-25 2012-03-01 株式会社バイオマトリックス研究所 がん細胞を用いた抗体の製造方法
US8598408B2 (en) 2010-08-25 2013-12-03 Ordermade Medical Research Inc. Method of producing an antibody using a cancer cell

Also Published As

Publication number Publication date
WO1997018300A3 (en) 1997-07-24
ATE261654T1 (de) 2004-04-15
WO1997018300A2 (en) 1997-05-22
US5986170A (en) 1999-11-16
EP0866655A2 (en) 1998-09-30
EP0866655B1 (en) 2004-03-17
US6284239B1 (en) 2001-09-04
DE69631896D1 (de) 2004-04-22
AU1158997A (en) 1997-06-05

Similar Documents

Publication Publication Date Title
JP2000500653A (ja) ヒト癌のマウスモデル
JP4267692B2 (ja) 前立腺癌の免疫療法のための樹状細胞の単離および／または保存
Mueller et al. Potential of the scid mouse as a host for human tumors
Uhr et al. Cancer dormancy: studies of the murine BCL1 lymphoma
Heinzerling et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses
DE69839273T2 (de) Krebsimmuntherapie mit semi-allogenen zellen
JP4236279B2 (ja) 異種移植に対する寛容性の発現のための代理寛容形成
JP6096677B2 (ja) 同種造血幹細胞移植の増強
JPH11508762A (ja) エフェクタ細胞調節用遺伝子療法
US20020006413A1 (en) Genetically engineered tumor cell vaccines
JPH05500617A (ja) 免疫処理された宿主におけるヒト末梢血液細胞
CN105873639A (zh) 自体肿瘤疫苗和方法
Ishida et al. Effects of the deregulated expression of human interleukin-2 in transgenic mice
JP2980986B2 (ja) 殺腫瘍性ｔリンパ球
JP2001520011A (ja) ヒトガンについてのマウスモデル
Rosenstein et al. In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor.
Perdrizet et al. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen.
Sauer et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells
JPH10504454A (ja) キメラ免疫無防備状態動物における長期間異種骨髄性およびリンパ性細胞生産
JPH08510131A (ja) 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用
Huppes et al. Cytokine Dependence of Human to Mouse Graft‐versus‐Host Disease
KR101651171B1 (ko) Il-12를 발현하는 간엽 줄기세포를 포함하는 간암 치료용 조성물 및 이를 이용한 치료방법
CN109891238A (zh) 免疫治疗剂的剂量确定
CA2237300C (en) Murine model for human carcinoma
Huss et al. Homing and immunogenicity of murine stromal cells transfected with xenogeneic MHC class II genes

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070813

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20071114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071225